November 16th, 2026Weekly review: Testosterone’s history, Peri-SS symptom scale, and moreGet caught up with Contemporary OB/GYN! This list helps you navigate our top stories from the week, all in one place.Read more
November 12th, 2026Peri-SS shows reliability for tracking perimenopause symptomsThe 16-item Perimenopause Symptom Scale showed strong reliability and validity among 1255 women aged 35 to 59 years in the United States.Read more
November 6th, 2026Q&A: Kanchi Chadha, MD, FACOG, MSCP, on FDA boxed warning removalsKanchi Chadha, MD, FACOG, MSCP, supports reconsidering MHT boxed warnings but says the FDA cited no study behind the change.Read more
November 5th, 2026Q&A: Soma Mandal, MD, MSCP, on FDA boxed warning removals for MHTSoma Mandal, MD, MSCP, says removing MHT boxed warnings is overdue but calls for transparency on the FDA's product-specific rationale.Read more
November 3rd, 2026Top video interviews from The Menopause Society 2026 Annual MeetingA recap of the top video interviews from Contemporary OB/GYN's coverage of The Menopause Society 2026 Annual Meeting in San Diego.Read more
November 2nd, 2026Reactions to FDA's boxed warning removals for menopausal hormone therapySusan Reed, MD, MPH, MS, and Calbeth C. Alaribe, DMSc, MPH, PA-C, CPCHE, weigh in on FDA boxed warning removals for menopausal hormone therapy.Read more
November 13th, 2026Testosterone in women: Androgenic adverse events and lab monitoringBlood levels alone cannot confirm safe testosterone dosing. Asking about androgenic effects and allowing months for response are central to care.Read more
November 13th, 2026Testosterone for women: Global consensus and physiologic dosingA global consensus defines what the evidence supports for testosterone in women. Benefits for strength, mood, and cognition lack randomized data.Read more